1536 related articles for article (PubMed ID: 27663795)
41. An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells.
Nakagawa H; Higurashi M; Ishikawa F; Mori K; Shibanuma M
Biochem Biophys Res Commun; 2023 Mar; 649():1-9. PubMed ID: 36738577
[TBL] [Abstract][Full Text] [Related]
42. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
[TBL] [Abstract][Full Text] [Related]
43. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
44. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
45. MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Tumour Biol; 2016 Apr; 37(4):4991-9. PubMed ID: 26537583
[TBL] [Abstract][Full Text] [Related]
46. Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype.
He Q; Jing H; Liaw L; Gower L; Vary C; Hua S; Yang X
Sci Rep; 2016 Mar; 6():23216. PubMed ID: 26976794
[TBL] [Abstract][Full Text] [Related]
47. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells.
Kruger JS; Reddy KB
Mol Cancer Res; 2003 Sep; 1(11):801-9. PubMed ID: 14517342
[TBL] [Abstract][Full Text] [Related]
48. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.
Banda M; Speyer CL; Semma SN; Osuala KO; Kounalakis N; Torres Torres KE; Barnard NJ; Kim HJ; Sloane BF; Miller FR; Goydos JS; Gorski DH
PLoS One; 2014; 9(1):e81126. PubMed ID: 24404125
[TBL] [Abstract][Full Text] [Related]
49. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
50. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer.
Blomme A; Costanza B; de Tullio P; Thiry M; Van Simaeys G; Boutry S; Doumont G; Di Valentin E; Hirano T; Yokobori T; Gofflot S; Peulen O; Bellahcène A; Sherer F; Le Goff C; Cavalier E; Mouithys-Mickalad A; Jouret F; Cusumano PG; Lifrange E; Muller RN; Goldman S; Delvenne P; De Pauw E; Nishiyama M; Castronovo V; Turtoi A
Oncogene; 2017 Apr; 36(15):2116-2130. PubMed ID: 27775075
[TBL] [Abstract][Full Text] [Related]
51. Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells.
Mander S; You DJ; Park S; Kim DH; Yong HJ; Kim DS; Ahn C; Kim YH; Seong JY; Hwang JI
Arch Pharm Res; 2018 Feb; 41(2):229-242. PubMed ID: 29196918
[TBL] [Abstract][Full Text] [Related]
52. IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
House CD; Grajales V; Ozaki M; Jordan E; Wubneh H; Kimble DC; James JM; Kim MK; Annunziata CM
BMC Cancer; 2018 May; 18(1):595. PubMed ID: 29801480
[TBL] [Abstract][Full Text] [Related]
53. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
[TBL] [Abstract][Full Text] [Related]
54. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
55. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
[TBL] [Abstract][Full Text] [Related]
56. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
57. Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids.
Carduner L; Picot CR; Leroy-Dudal J; Blay L; Kellouche S; Carreiras F
Exp Cell Res; 2014 Jan; 320(2):329-42. PubMed ID: 24291221
[TBL] [Abstract][Full Text] [Related]
58. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
59. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis.
Dutta P; Sarkissyan M; Paico K; Wu Y; Vadgama JV
Breast Cancer Res Treat; 2018 Aug; 170(3):477-486. PubMed ID: 29594759
[TBL] [Abstract][Full Text] [Related]
60. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Wang S; Yao Y; Yao M; Fu P; Wang W
Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]